MedPath

(Ro 24-2027) A Randomized, Double-Blind, Comparative Study of Dideoxycytidine (ddC) Versus Zidovudine (AZT) in Patients With AIDS or Advanced ARC

Phase 2
Completed
Conditions
HIV Infections
Registration Number
NCT00000679
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Brief Summary

To show that zalcitabine (dideoxycytidine; ddC) is at least as effective as zidovudine (AZT) in the treatment of AIDS or advanced AIDS related complex (ARC), and also that ddC shows a different safety profile than AZT.

In clinical studies, ddC shows antiviral activity. Because of the antiviral activity, and because of the low incidence of mild, reversible neurotoxicity and absence of blood-related toxicity with low dose ddC therapy, a long-term Phase II/III study comparing ddC to AZT in patients with AIDS or advanced ARC is now warranted.

Detailed Description

In clinical studies, ddC shows antiviral activity. Because of the antiviral activity, and because of the low incidence of mild, reversible neurotoxicity and absence of blood-related toxicity with low dose ddC therapy, a long-term Phase II/III study comparing ddC to AZT in patients with AIDS or advanced ARC is now warranted.

After screening, physical examination and laboratory tests (within 14 days of entry) patients are randomized to one of two treatment groups. They receive either ddC plus an AZT placebo or AZT plus a ddC placebo. Because it is a blinded study, patients do not know which group they are in. Patients are evaluated weekly for the first 10 weeks and then biweekly thereafter.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
600
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (25)

Graduate Hosp

🇺🇸

Philadelphia, Pennsylvania, United States

New England Med Ctr

🇺🇸

Boston, Massachusetts, United States

Ctr for Special Immunology

🇺🇸

Fort Lauderdale, Florida, United States

Bowman Gray School of Medicine / North Carolina Baptist Hosp

🇺🇸

Winston-Salem, North Carolina, United States

N Texas Ctr for AIDS & Clin Rsch

🇺🇸

Dallas, Texas, United States

Santa Clara Valley Med Ctr

🇺🇸

San Jose, California, United States

Saint Michael's Med Ctr

🇺🇸

Newark, New Jersey, United States

Kaiser Permanente Med Ctr

🇺🇸

Los Angeles, California, United States

Northwestern Univ Med School

🇺🇸

Chicago, Illinois, United States

Georgetown Univ Med Ctr

🇺🇸

Washington, District of Columbia, United States

Rush Presbyterian - Saint Luke's Med Ctr

🇺🇸

Chicago, Illinois, United States

AIDS Research Consortium of Atlanta

🇺🇸

Atlanta, Georgia, United States

UCD Med Ctr

🇺🇸

Sacramento, California, United States

Kaiser Foundation Hosp

🇺🇸

Harbor City, California, United States

Henry Ford Hosp

🇺🇸

Detroit, Michigan, United States

Univ Hosp of Cleveland / Case Western Reserve Univ

🇺🇸

Cleveland, Ohio, United States

Univ TX Galveston Med Branch

🇺🇸

Galveston, Texas, United States

Sunset Park Health Ctr - Lutheran Med Ctr

🇺🇸

Brooklyn, New York, United States

Davies Med Ctr

🇺🇸

San Francisco, California, United States

Mount Zion Med Ctr

🇺🇸

San Francisco, California, United States

San Francisco Veterans Administration Med Ctr

🇺🇸

San Francisco, California, United States

Med Service

🇺🇸

Miami, Florida, United States

Baylor College of Medicine

🇺🇸

Houston, Texas, United States

Comprehensive Clinic / Dr Robert Schwartz

🇺🇸

Fort Myers, Florida, United States

Albany Med College / AIDS Treatment Ctr

🇺🇸

Albany, New York, United States

© Copyright 2025. All Rights Reserved by MedPath